Literatur zur Patienteninformation Lungenkrebs

Diese Patienteninformationen beruhen auf der SOP „Nicht-kleinzelliges Bronchialkarzinom - Empfehlungen zu Diagnostik, Therapie und Nachsorge“ des Centrums für Onkologie Köln.

Diese basieren auf folgende Literatur:

1. Abratt RP, Szczesna K, Mattson M et al: Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)- final results of the Glob 2 phase III with patient benefit analysis. Proc. Ann. Meeting ASCO, abstract 7016, 2004.
2. Alberola V, Camps C, Provencio M et al: Cisplatin plus gemcitabine versus a ciplatin-based triplet versus nonplatinum sequential doublets in advanced nln-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21: 3207-3213, 2003.
3. Armstrong J: Target volume definition for three-dimensional conformal radiation therapy of lung cancer. Br J Radiol 71:587-594, 1998.
4. Arriagada R, Bergman B, Dunant, International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004.
5. Asamura H, Nakayama H., Kondo H., Tsuchiya R et al: Lobe-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis. J Thorac Cardiovasc Surg 117: 1102-1111, 1999.
6. Asamura H, Suzuki K, Watanabe S et al : Clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions. Ann Thorac Surg 76: 1016-1022, 2003.
7. Becker H, Drings P, Havemann K et al: Therapie des nicht-kleinzelligen Lungenkarzinoms.  Kurzgefasste Interdisziplinäre Leitlinien 2002, Deutsche Krebsgesellschaft. In: Qualitätssicherung in der Onkologie, W.Zuckschwerdt Verlag, 121-141, 2002.
8. Birkmeyer JD, Siewers AE, Finlayson EV et al:  Hospital volume and surgical mortality in the United States. N Engl J Med 346: 1128-1137, 2002.
9. British Thoracic Society: BTS guidelines on the selection of patients with lung cancer for surgery. Thorax 56: 89-108, 2001.
10. Dartevelle P, Marzelle J, Chapelier A et al: Extended operations for T3-T4 primary lung cancers. Indications and results. Chest 96: 51S8-538, 1989.
11. Dartevelle PG, Chapelier AR, Macchiarini P et al: Anterior transcervical-thoracic approach for radical resection of lung tumors invading the thoracic inlet. J Thorac Cardiovasc Surg 105: 1025-34, 1993.
12. Datta D and Lahiri B: Preoperative evaluation of patients undergoing lung resection surgery. Chest. 123: 2096-2103, 2003.
13. Deslauriers J and Gregoire J: Surgical therapy of early non-small cell lung cancer: Chest 117: 104S-109S, 2000.
14. Deslauriers J, Gregoire J, Jacques LF et al:  Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences. Ann Thorac Surg 77: 1152-1156 (discussion 1156), 2004.
15. Dillman RO, Seagren SL, Propert KJ et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990.
16. Douillard J.Y.  [7013] ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. ASCO 2005.
17. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66-72, 1999.
18. Ellis PA, Smith I, Hardy J et al: Symptom relief with MVP (mitomycin C, vinblastin and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer 71:366-370, 1995.
19. Errett LE, Wilson J, Chiu RC et al: Wedge resection as an alternative procedure for peripheral bronchogenic carcinoma in poor-risk patients. J Thorac Cardiovasc Surg 90: 656-61, 1985.
20. Evans TL: Highlights from the Tenth World Conference on Lung Cancer. The Oncologist 9:232-238, 2004.
21. Fosella F: Secon-line chemotherapy for non-small-cell lung cancer. Curr Oncology Reports 2:96-101, 2000.
22. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with Mitomycin, Vindesine, and Cisplatin in unresectable stage III non-small lung cancer. J Clin Oncol 17: 2692-2699 (1999).
23. Ginsberg RJ and Rubinstein LV: Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 60: 615-22 ( discussion 622-3), 1995.
24. Ginsberg R, Roth J, Fergusson, M: Lung cancer surgical practice guidelines. Society of Surgical Oncology practice guidelines. Oncology (Huntingt). 11: 889-92, 1997.
25. Ginsberg RJ: Lung cancer surgery: acceptable morbidity and mortality, expected results and quality control. Surg Oncol 11: 263-266, 2002.
26. Gridelli C, Perrone F, Gallo C et al: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. JNCI 95:362-370, 2003.
27. Gridelli C, Gallo C, Shepherd FA et al: Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3025-3034, 2003.
28. Hann N, Shepherd FA, Fossella FV et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004.
29. Hoffmann H, Dienemann H: Invasives Lymphknotenstaging. S.61-65. In: Management des Lungenkarzinoms. Drings, Dienemann, Wannemacher (eds), Springer Verlag 2003.
30. Jensik RJ, Faber LP, Kittle CF. Segmental resection for bronchogenic carcinoma, Ann Thorac Surg 28: 475-483, 1979.
31. Laack E, Dichgreber N, Müller T et al: Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 22, 2348-2356, 2004.
32. Landheer ML, Therasse P, van de Velde CJ: Quality assurance in surgical oncology (QASO) within the European Organization for Research and Treatment of Cancer (EORTC): current status and future prospects. Eur J Cancer 37: 1450-1462, 2001.
33. LeChevalier TL, Brisgand D, Douillard JY et al: Radnomized Study of Vinorelbine and Cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994.
34. Martin J, Ginsberg RJ, Abolhoda A et al: Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 72: 1149-1154, 2001.
35. Miller JI and Hatcher CR: Limited resection of bronchogenic carcinoma in the patient with marked impairment of pulmonary function. Ann Thorac Surg 44: 340-343, 1987.
36. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111:1710-1717,  1997.
37. Mountain CF and Dresler CM: Regional lymph node classification for lung cancer staging, Chest. 111: 1718-1723,1997.
38. Naruke T, Suemasu K, Ishikawa S: Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 76: 832-829, 1978.
39. Naruke T, Goya T, Tsuchiya R et al: Prognosis and survival in resected lung carcinoma based on the neuw international staging system. J Thorac Cardiovasc Surg 96:440-447, 1988.
40. Naruke T, Tsuchiya R, Kondo H et al: Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 71: 1759-1764, 2001.
41. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995.
42. Pfister DG, Johnson DH, Azzoli G et al: Amercian Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 22:330-353, 2004.
43. Robinson LA, Wagner H, Ruckdeschel JC : Treatment of stage IIIA non-small cell lung cancer. Chest 123: 202S-220S, 2003.
44. Rosell R, Gomez-Codina J, Camps C et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153-158, 1994.
45. Roth J, Fossela F, KomakR et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in respectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86:673-680, 1994.
46. Schirren J, Richter W, Schneider P et al: I. Principles and results of systematic lymph node dissection in surgically treated bronchial carcinoma: Chirurg 67: 869-8676, 1996.
47. Sandler A. B.  et al.:[LBA4] Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599, ASCO 2005.
48. Scott WJ, Howington J and Movsas B: Treatment of stage II non-small cell lung cancer. Chest 123: 188S-201S, 2003.
49. Shepherd F, Dancey J, Ramlau R: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000.
50. Shepherd FA, Pereira J, Ciuleanu TE et al: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 2st line or 2nd line chemotherapy. A National Cancer Intitute of Canada Clinical Trials Group (NCIC CTG) trial.  Proc. Ann Meeting ASCO,  abstract 7022, 2004.
51. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32.
52. Schiller JH, Harrington D, Belani C et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med 346:92-98 (2003).
53. Silvestri GA, Handy J, Lackland D et al: Specialists achieve better outcomes than generalists for lung cancer surgery. Chest 114: 675-680, 1998.
54. Smit EF, van Meerbeeck J, Lianes P et al: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group – EORTC 08975. J Clin ONcol 21:3909-3917, 2003.
55. Smythe WR: Treatment of stage I non-small cell lung carcinoma. Chest 123: 181S-187S, 2003.
56. Strauss GM, Herndonn J, Maddaus MA et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. ASCO Ann Meeting Proc 22, abstract 7019, 2004.
57. Strauss G. M. et al. Adjuvant chemotherapy in stage IB NSCLC: Update of Cancer and Leukemia Group B (CALBG) protocol 9633. Abstract 7007, ASCO 2006.
58. Thomas M, Macha HN, Ukena D et al: Cisplatin / etoposide (PE) followed by twice-daily chemoradiation (hfRT/CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC): A randomized phase III trial of the German Lung Cancer Cooperative Group (GLCCG). ASCO Ann Meeting Proc 22, abstract 7004, 2004.
59. Travis WD, Colgy TV, Corrin B et al: Histological typing of lung and pleural tumors. 3rd etn. Springer, Berlin Heidelberg New York Tokyo, 1999 .
60. Vansteenkiste JF, Vandebroek JE, Nackaerts KL et al: Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine vesus cisplatin-vindesine. Ann Oncol 12:1221-1230, 2001.
61. Wassermann, K: Editorial Palliativmedizin. Atemw- Lungenkrkh 29: 139-141, 2003.
62. Winton TL, Livingston R, Johnson et al, National Cancer Institute of Canada: A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non small cell lung cancer (NSCLC) Intergroup JBR.10. ASCO Ann Meeting Proc 22, abstract 7018, 2004.
63. Yokoi K, Kamiya N, Matsuguma H et al: Detection of brain metastasis in potentially operable non-small cell lung cancer: A comparison  of CT and MRI. Chet 115:714-719, 1999.
64. Zähringer M, Lackner K: Interventionell-radiologische Therapieoptionen bei oberer und unterer Einflußstauung. Atemw.- Lungenkrankrkh: 30:69-77, 2004.